Psychedelic therapy

Psychedelic therapy is the administration of a psychoactive drug, most often psilocybin or MDMA, in a small number of supervised sessions framed by preparatory meetings and follow-up discussion with trained personnel. What distinguishes it from ordinary psychopharmacology is the claim that one or two sessions, rather than daily medication, can produce durable change in depression, post-traumatic stress disorder, or addiction. Randomized trials in patient populations have reported large short-term effects. Whether those effects belong to the drugs is the question the field has not resolved, because almost everyone involved can tell who received what.

§How it works

Classical psychedelics act as agonists or partial agonists at the serotonin 5-HT2A receptor; in human volunteers, pretreatment with a 5-HT2A antagonist blocks most of the subjective effects, the clearest evidence that the experience depends on this receptor. Neuroimaging during the acute state finds increased diversity of spontaneous cortical signals and reduced segregation between large-scale networks, which has made these drugs a tool in the study of Neural correlates of consciousness apart from any therapeutic use. In rodents and cultured neurons, psychedelics and ketamine promote dendritic spine growth and synapse formation in cortex.¹ Nothing equivalent has been measured in a living human brain.

The rationale is that the acute state opens a window in which entrenched patterns of thought become revisable, and that the psychological support around the session determines what fills it. Preparation, a dosing session of several hours with two attendants, and later integration meetings all count as part of the intervention rather than as scaffolding around a pill. The pharmacology clears within a day; the psychological content does not, which is both the intended effect and the source of the main harms.

Terminology

The phrase covers three unrelated pharmacologies. Psilocybin and LSD are 5-HT2A agonists. MDMA is an entactogen, a monoamine releaser that heightens feelings of closeness and blunts fear responses without much perceptual change; calling it a psychedelic is a convenience of practice, not a claim about mechanism. Ketamine is a dissociative NMDA-receptor antagonist whose antidepressant effect is rapid and short-lived.

§Development history

1. 1938–1943
   LSD synthesised, then discovered
   Albert Hofmann makes LSD at Sandoz in 1938 and identifies its psychoactivity five years later; the company distributes it to psychiatric researchers.
2. 1958
   Psilocybin isolated
   Hofmann isolates the active compound from Psilocybe mushrooms; Sandoz markets it to researchers as Indocybin.
3. 1970
   Schedule I in the United States
   The Controlled Substances Act places LSD and psilocybin in the most restrictive category, and clinical work in the West effectively stops for two decades.
4. 1985
   MDMA scheduled
   The DEA places MDMA in Schedule I on an emergency basis, over objections from psychotherapists who had been using it; the placement is challenged in court and later made permanent.
5. 2006
   The revival's founding study
   Griffiths and colleagues at Johns Hopkins report that psilocybin reliably occasions experiences volunteers rate as personally meaningful, re-establishing the drug as a legitimate subject of study.
6. 2016
   Distress in cancer patients
   Randomized crossover trials at Johns Hopkins and NYU report substantial reductions in depression and anxiety among patients with life-threatening cancer.
7. 2019
   Esketamine approved
   The FDA approves esketamine nasal spray for treatment-resistant depression, restricted to certified clinics under a risk-management programme.
8. 2021
   A comparator and a phase 3
   Psilocybin fails to beat escitalopram on the primary outcome of a head-to-head depression trial, while MAPS reports a positive phase 3 of MDMA-assisted therapy for PTSD.
9. 2023
   Australia opens a pathway
   The Therapeutic Goods Administration permits authorised psychiatrists to prescribe MDMA for PTSD and psilocybin for treatment-resistant depression, the first such national framework.
10. 2024
    The FDA declines
    An advisory committee votes against MDMA-assisted therapy on both effectiveness and benefit–risk, and the agency asks Lykos Therapeutics, the renamed MAPS corporate arm, for an additional phase 3 trial.

The first clinical wave, from the 1950s to about 1970, produced a large literature and little that survives scrutiny: open-label case series, token controls, outcomes chosen after the fact. Prohibition ended it before the methodology improved. The revival was built to avoid a repeat, which makes its central design flaw more striking, not less.

§Clinical evidence

The strongest results come from narrow, severely ill populations. In patients with life-threatening cancer, single psilocybin sessions with psychological support produced large reductions in depression and anxiety lasting months.² In treatment-resistant depression, a company-sponsored phase 2b trial of the synthetic formulation COMP360 found a dose-related reduction in depression scores at three weeks, with the advantage over the lowest comparator dose narrowing by week twelve; serious adverse events, including suicidal ideation and self-injurious behaviour, occurred and were not confined to one arm.³ Compass Pathways has since taken COMP360 into a phase 3 programme in the same indication and announced topline results the company describes as positive. No psilocybin product had been approved by any major regulator as of mid-2026.

The one head-to-head test against a standard antidepressant is instructive. Psilocybin did not outperform escitalopram on the primary outcome; several secondary measures favoured it, but those were not corrected for multiple comparisons and the authors said so.⁴ For PTSD, MAPS reported a phase 3 trial in which MDMA-assisted therapy reduced clinician-rated symptom severity more than placebo delivered with the same psychological support.⁵

Ketamine is the exception that clarifies the rest. Its antidepressant effect appears within hours and is well replicated, and esketamine, marketed as Spravato, is approved in the United States and elsewhere for treatment-resistant depression, the only member of this loose family to clear a regulator. Even here expectancy is hard to exclude: masked by general anaesthesia during surgery, ketamine did not separate from placebo, and both groups improved markedly.⁶

§The blinding problem

A person given an active dose knows it within an hour, and so does the therapist sitting with them. Guess rates approach ceiling for both parties, which means the double-blind design that licenses causal inference in drug trials is not actually operating.⁷ Inert placebos are transparent; active comparators such as niacin or a very low dose of the same drug reduce the problem without removing it.

The confound compounds. Participants are recruited from populations enthusiastic about psychedelics, arrive with strong expectations, and are assessed on scales that depend on their own report or a clinician's judgement rather than on anything measurable. The therapists are unblinded and typically advocates. Sham-controlled trials of Non-invasive neuromodulation and Deep brain stimulation face a milder version of the difficulty, but no sham resembles several hours of altered consciousness.

What the FDA actually said

The 2024 rejection was not a safety refusal. The advisory committee's objections centred on functional unblinding, on the impossibility of separating the drug from an unstandardized psychotherapy the agency does not regulate, and on missing data about durability and abuse potential.⁸ In the same month the journal Psychopharmacology retracted three papers reporting earlier MDMA trial data, citing undisclosed unethical conduct at one site.

The FDA's 2023 draft guidance asks sponsors to measure expectancy and characterize the psychotherapy component, and stops short of a remedy, because none is known.⁹

§Regulation and access

Two regulatory tracks are routinely conflated. The medical track runs through drug regulators, and on it only esketamine has succeeded; the agency later approved its use without a concurrent oral antidepressant. Australia's Therapeutic Goods Administration opened a narrower door in 2023, allowing specifically authorised psychiatrists to prescribe MDMA for PTSD and psilocybin for treatment-resistant depression.

The second track is not medical. Oregon's Measure 109, passed in 2020, created a state-licensed psilocybin services programme, operating since 2023: adults may consume psilocybin with a trained facilitator at a licensed centre, with no diagnosis, no prescription, and no claim of treating anything. Colorado's Proposition 122 established a comparable healing-centre framework. Neither is an approval, neither generates controlled outcome data, and calling them legalized psychedelic medicine misstates what voters passed.

Cost constrains the medical track: the active ingredient is cheap, a full day of two clinicians' time is not, which places the intervention inside the problems catalogued in Access and inequality. Scheduling from the first wave remains in force in most jurisdictions, an application of the Precautionary principle critics blame for decades of lost evidence.

§Risks

Serious harms exist and are concentrated in the people trials exclude. A personal or family history of psychotic or bipolar disorder is a standard exclusion criterion, so little is known about giving these drugs to the population most plausibly at risk of a precipitated psychotic episode. Blood pressure and heart rate rise transiently, which matters for MDMA in anyone with cardiac disease. Prolonged psychological difficulty after a session is reported in surveys of non-clinical users at rates that are not negligible.

A distinct hazard follows from the mechanism. A drug that heightens suggestibility, trust, and emotional openness leaves the person receiving it unusually dependent for several hours, which is why documented boundary violations at a trial site were read as structural rather than isolated. The ethical questions here concern the therapist relationship at least as much as the drug.

§Healthy people and enhancement

The evidence base is entirely clinical. Claims that psychedelics improve creativity, wellbeing, or moral sensibility in people without a diagnosis are not supported by controlled work. The healthy-volunteer literature is small, its samples are rarely representative, and its outcomes are overwhelmingly self-rated questionnaires administered to people who know what they took. Microdosing has been tested more rigorously than much of the field, in a self-blinding citizen-science study whose participants randomized their own capsules: the reported benefits appeared in the placebo condition too.¹⁰ Subjective improvement outruns measured change, the pattern the literature on Nootropics keeps finding and the one self-tracking cannot correct for.

Advocates within Human enhancement circles nonetheless treat these compounds as candidate tools, framing supervised access as an instance of Morphological freedom and prosocial effects as a route to Moral enhancement. Bioconservative critics answer in the terms Leon Kass set out against pharmacological mood improvement: a chemically induced sense of meaning is not meaning. Ego dissolution draws philosophical interest for what it might show about Personal identity and continuity, though a first-person report of self-loss is evidence about the report. The unregulated market, overlapping with Biohacking and grinders and with mushroom products sold under the post-market rules described in Dietary supplements, has no outcome data.

§Outlook

Three things would move the field. The first is the additional MDMA phase 3 the FDA requested, together with the psilocybin phase 3 programme, read for effect sizes rather than headlines. The second is a design that measures the drug's contribution instead of assuming it: prespecified expectancy assessment, blinded independent raters, dose–response comparisons among active arms. The third is pharmacological. Analogues engineered to keep the plasticity-promoting effects without the subjective experience have shown antidepressant-like effects in rodents; one that worked in humans would settle whether the experience is necessary and restore the blind at once.

Is the trip required

One camp holds that the acute experience is the therapy, that its intensity predicts outcome, and that a non-hallucinogenic analogue would be a different drug. The other holds that the experience is a side effect of engaging a plasticity mechanism, and that the intensity–outcome correlation is what expectancy alone would produce. No human trial has separated them.

The strongest objection to the field is not that its drugs are dangerous or its trials fraudulent. It is that after two decades of revival, no study has distinguished the effect of the drug from the effect of believing one received it.

§See also

• Nootropics
• Non-invasive neuromodulation
• Deep brain stimulation
• Neural correlates of consciousness
• Human enhancement
• Moral enhancement
• Bioethics of enhancement
• Access and inequality

§References